Autopsy report · NCT02806362

Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

“Study halted prematurely, prior to enrollment of first participant”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

AbbVie

Sponsor type

Industry

Conditions

Chronic Hepatitis C Virus

Interventions

Ombitasvir/paritaprevir/ritonavir

Participants

0

Trials that died the same way

• Tiotropium Handihaler vs. Tiotropium Respimat in COPD
  “Study halted prematurely due to funding, prior to enrollment of first participant” (93% match in meaning)
• High Cut Off Dialysis in Systemic Inflammatory Response Syndrome Patients After Cardiac Surgery
  “Study halted prematurely, prior to enrollment of first patient, due to recruiting problems.” (87% match in meaning)
• Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
  “Withdrawn: study halted prematurely, prior to enrollment of first participant” (85% match in meaning)
• An Exploratory Clinical Study of GC012F Injection for Refractory gMG
  “The study stopped early, before enrolling its first participant.” (84% match in meaning)
• Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
  “The study was halted because enrollment was too slow” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.